Earnings summaries and quarterly performance for Werewolf Therapeutics.
Executive leadership at Werewolf Therapeutics.
Board of directors at Werewolf Therapeutics.
Research analysts covering Werewolf Therapeutics.
Recent press releases and 8-K filings for HOWL.
Werewolf Therapeutics, Inc. Provides Pipeline Update and Outlines 2026 Priorities
HOWL
New Projects/Investments
Guidance Update
- Werewolf Therapeutics, Inc. issued a press release on December 18, 2025, announcing a pipeline update and business overview of its priorities for 2026, including a focus on its INDUCER T-cell engager platform.
- The company reported compelling data from the Phase 1/1b clinical trial for WTX-124 as of October 30, 2025, showing objective, durable responses as a monotherapy in melanoma, cutaneous squamous cell carcinoma, and gastroesophageal junction cancer, with a 21% objective response rate in heavily pretreated melanoma patients. The FDA accepted 18 mg as the recommended dose and provided guidance for a monotherapy registration path in melanoma.
- For WTX-330, additional evidence of highly favorable tolerability and antitumor activity was observed in the Phase 1b/2 clinical trial as of October 31, 2025, including one confirmed partial response in metastatic gall bladder cancer with a 45% reduction in tumor target lesions as of December 2, 2025.
- Werewolf Therapeutics is seeking strategic partnerships for further development of its WTX-124 and WTX-330 INDUKINE programs.
- The company plans IND filings for its INDUCER molecules WTX-1011 and WTX-2022 in mid-2027, pending additional funding.
Dec 18, 2025, 1:24 PM
Werewolf Therapeutics Provides Pipeline Update and 2026 Priorities
HOWL
New Projects/Investments
Guidance Update
- Werewolf Therapeutics announced a pipeline update, including initial Phase 1b expansion arm data for WTX-124 showing a 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or metastatic cutaneous melanoma patients.
- Initial data from the WTX-330 Phase 1b/2 trial demonstrated additional evidence of antitumor activity and a highly favorable tolerability profile.
- The company expects an additional Phase 1/1b data update for WTX-124 and completion of Part A of the WTX-330 Phase 1b/2 clinical trial in the first half of 2026.
- Werewolf is seeking strategic partnerships for the further development of its WTX-124 and WTX-330 INDUKINE programs, noting that additional funding will be required.
- The company is advancing two INDUCER T cell engager development candidates, WTX-1011 and WTX-2022, with two IND filings planned by mid-2027.
Dec 18, 2025, 1:00 PM
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
HOWL
Earnings
Guidance Update
New Projects/Investments
- Werewolf Therapeutics, Inc. reported a net loss of $16.4 million for the third quarter of 2025 and held $65.7 million in cash and cash equivalents as of September 30, 2025, which is expected to fund operations into the fourth quarter of 2026.
- The company received Fast Track Designation from the US FDA for WTX-124 for the potential treatment of patients with locally advanced or metastatic cutaneous melanoma.
- Updates on the WTX-124 Phase 1/1b clinical trial interim data and feedback from an End of Phase 1 meeting with the FDA, as well as an update on the WTX-330 Phase 1b/2 clinical trial, are anticipated in the fourth quarter of 2025.
- WTX-1011, the company's first INDUCER T-cell engager development candidate, continues IND-enabling studies, with a plan to nominate a differentiated target candidate by year-end 2025.
Nov 4, 2025, 12:07 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more